Clinical Trials Sponsored by Cangene Corporation

Total 8477 results

Southeastern Gynecologic Oncology
Celgene Corporation

Completed

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
NSABP Foundation Inc
Celgene Corporation

Completed

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

Breast Neoplasms

United States
Winthrop University Hospital
Celgene Corporation

Terminated

Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis

Chronic Pancreatitis
M.D. Anderson Cancer Center
Celgene Corporation

Active, not recruiting

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Lymphoma | Leukemia

United States
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer... and other conditions

United States, Canada
Technical University of Munich
Celgene Corporation

Completed

An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema (APREMINUM)

Eczema | Nummular Eczema | Dermatitis Eczema | Nummular Dermatitis

Germany
Rush University Medical Center
Celgene Corporation

Terminated

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

MDS

United States
University Health Network, Toronto
Celgene Corporation

Completed

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin Disease
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Chronic Lymphocytic Leukemia

United States
University of Wisconsin, Madison
Celgene Corporation

Completed

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Universitaire Ziekenhuizen KU Leuven
Celgene Corporation

Completed

Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel (QOLINPAC)

Pancreatic Cancer

Belgium
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

Myeloma

United States
Dartmouth-Hitchcock Medical Center
Celgene Corporation

Terminated

Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)

Neuropathy | Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)

United States
Dartmouth-Hitchcock Medical Center
Celgene Corporation

Withdrawn

Apremilast Therapy for Acute Gouty Arthritis

Acute Gout

United States
Dana-Farber Cancer Institute
Celgene Corporation

Terminated

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck | Basaloid Squamous Cell Carcinoma | Undifferentiated Carcinoma | Adenosquamous Cell Carcinoma
Loyola University
Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States
University Health Network, Toronto
Celgene Corporation

Completed

Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Canada
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Pancreatic Cancer Research Team
Celgene Corporation

Completed

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

Resectable Pancreatic Cancer

United States
NYU Langone Health
Unicorn Pacific Corporation

Terminated

A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Solid Tumors

United States
Columbia University
Celgene Corporation; Schering-Plough

Unknown

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Soft Tissue Sarcoma | Mesothelioma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Ph II Study of Azacitidine in Myelofibrosis

Myelofibrosis

United States
Florida Academic Dermatology Centers
Celgene Corporation

Unknown

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma (REvMM2009)

Cutaneous T Cell Lymphoma

United States
Virginia Clinical Research, Inc.
Celgene Corporation

Unknown

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

Lichen Planus

United States
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
German Breast Group
Celgene Corporation; Amgen

Completed

Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Roswell Park Cancer Institute
Celgene Corporation

Completed

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Lymphoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide for Patients With Myelofibrosis (MF)

Myelofibrosis

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

Melanoma | Brain Neoplasms

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Thalidomide-Dexamethasone for Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Hematologic Disorder

United States
Michaela Liedtke
Celgene Corporation

Completed

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Paclitaxel in Prostate Cancer

Prostate Cancer

United States
University Health Network, Toronto
Celgene Corporation

Completed

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

Head and Neck Cancer

Canada
University Health Network, Toronto
Celgene Corporation

Completed

Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

Canada
Groupe Francophone des Myelodysplasies
Celgene Corporation

Unknown

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (GFM-Chimio-Rev)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

France
Cristina Gasparetto
Celgene Corporation

Completed

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
SCRI Development Innovations, LLC
Celgene Corporation

Completed

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

The Effects of Thalidomide on Symptom Clusters

Advanced Cancers

United States
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Advanced Cancers

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Leukemia | Myelodysplastic Syndrome

United States

Clinical Trials Sponsored by Cangene Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations